Black Rock Inc. Bicycle Therapeutics PLC Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Black Rock Inc. holds 575,030 shares of BCYC stock, worth $11.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

575,030

Previous 501,623 14.63%

Holding current value

$11.4 Million

Previous $9.07 Million 57.88%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$16.75 - $26.1 $1.23 Million - $1.92 Million	73,407 Added 14.63%	575,030 $14.3 Million
Q4 2023 Feb 13, 2024	BUY	$13.29 - $22.2 $4.09 Million - $6.83 Million	307,539 Added 158.46%	501,623 $9.07 Million
Q3 2023 Nov 13, 2023	BUY	$19.9 - $26.25 $258,222 - $340,620	12,976 Added 7.16%	194,084 $3.9 Million
Q2 2023 Aug 11, 2023	BUY	$18.95 - $28.67 $41,235 - $62,385	2,176 Added 1.22%	181,108 $4.62 Million
Q1 2023 May 12, 2023	SELL	$20.02 - $31.37 $217,937 - $341,493	-10,886 Reduced 5.73%	178,932 $3.81 Million

Q4 2022 Feb 13, 2023	BUY	$20.37 - $32.9 $178,665 - $288,565	8,771 Added 4.84%	189,818 $5.62 Million
Q3 2022 Nov 14, 2022	SELL	$17.49 - $28.44 $175,931 - $286,077	-10,059 Reduced 5.26%	181,047 $4.21 Million
Q2 2022 Aug 12, 2022	BUY	$12.95 - $46.99 $12,652 - $45,909	977 Added 0.51%	191,106 $3.21 Million
Q1 2022 May 12, 2022	SELL	$40.12 - $59.5 $556,303 - $825,027	-13,866 Reduced 6.8%	190,129 $8.34 Million
Q4 2021 Feb 10, 2022	BUY	$41.7 - $61.14 $8.51 Million - $12.5 Million	203,995 New	203,995 $12.4 Million

Others Institutions Holding BCYC

# of Institutions

Shares Held

30.6M

Call Options Held

85.5K

Put Options Held

11.6K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $588M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account